利伐沙班在下肢深静脉血栓溶栓治疗中的应用效果分析  

Application effect analysis of rivaroxaban in the treatment of deep vein thrombosis of lower extremity

作　　者：周小慧[1] 乔威[2] 王小敏[1] Zhou Xiaohui;Qiao Wei;Wang Xiaomin(Department of Pharmacy,Jiangsu Province Hospital of Chinese Medicine,Nanjing 210029,Jiangsu,China;Department of Vascular Surgery,Jiangsu Province Hospital of Chinese Medicine,Nanjing 210029,Jiangsu,China)

机构地区：[1]江苏省中医院药学部,江苏南京210029 [2]江苏省中医院血管外科,江苏南京210029

出　　处：《血管与腔内血管外科杂志》2022年第10期1192-1195,1216,共5页Journal of Vascular and Endovascular Surgery

摘　　要：目的探究利伐沙班在下肢深静脉血栓(DVT)溶栓治疗中的抗凝效果及安全性。方法收集2021年1月至2021年12月于江苏省中医院接受治疗的71例下肢DVT患者的临床资料。比较两组患者的抗凝治疗效果、治疗前后的下肢周径差及患肢静脉血流速度、血清因子水平及用药阶段抗凝药物相关不良反应的发生情况。结果观察组患者的抗凝治疗有效率高于对照组患者,差异有统计学意义(P<0.05)。治疗后,观察组患者的下肢周径差低于对照组患者,患肢静脉血流速度高于对照组患者,差异均有统计学意义(P<0.05)。治疗后,观察组患者的D-D水平低于对照组患者,PT、APTT均短于对照组患者,差异均有统计学意义(P<0.05)。观察组患者抗凝药物相关不良反应的发生率低于对照组患者,差异有统计学意义(P<0.05)。结论利伐沙班用于下肢DVT的溶栓治疗,不仅可确保获得良好的抗凝效果,还可避免凝血功能指标的异常波动,减少不良反应。Objective To investigate the anticoagulation effect and safety of rivaroxaban in the thrombolytic therapy of lower extremity deep vein thrombosis(DVT).Method The clinical data of a total of 71 patients with lower extremity DVT who were treated in Jiangsu Province Hospital of Chinese Medicine from January 2021 to December 2021 were collected.The anticoagulant treatment effect,lower extremity circumference difference before and after treatment,the venous blood flow velocity of the affected extremity,serum factor levels,and the occurrence of anticoagulant drug-related adverse events in the two groups were compared.Result The objective response rate of anticoagulation in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the lower extremity circumference difference of the observation group was lower than that of the control group,the venous blood flow velocity of the affected extremity was higher than that of the control group,and the differences were statistically significant(P<0.05).After the treatment,the D-D level of the observation group was lower than that of the control group,PT and APTT were shorter than those of the control group,and the differences were statistically significant(P<0.05).The incidence rate of anticoagulantrelated adverse events in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The employment of rivaroxaban in thrombolytic therapy for lower extremity DVT could not only ensure satisfactory anticoagulation effect but also avoid abnormal fluctuations in coagulation function indexes and reduce adverse events.

关 键 词：下肢 深静脉血栓 溶栓 利伐沙班 有效性 安全性 

分 类 号：R543[医药卫生—心血管疾病]